---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126323"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:57:47.340294+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks

## Summary
- Cash $291.8M as of Sept 30, 2024; runway into late 2026.
- Net loss $23.2M (Q3 2024) vs $20.8M (Q3 2023); R&D expenses $21.3M.
- ELVN-001 Phase 1: cumulative MMR 44% (8/18) by 24 weeks; no dose reductions at ≥40 mg due to TRAEs.
- Plan to report additional ELVN-001 data in 2025 with ~60-100 patients across lines of therapy.
- ELVN-002 trials in HER2+ MBC and CRC ongoing; data anticipated in 2025.

## SEC filing metadata
- accession: 0000950170-24-126323
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017024126323/0000950170-24-126323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017024126323/elvn-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126323
- JSON: https://secwatch.observer/filing/0000950170-24-126323.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.